Beyond LDL Cholesterol: Do Statins Have Other Roles?

November 8 - 12, 2008, New Orleans, Louisiana

Linda Brookes, MSc


February 16, 2009

In This Article


The question continues... do statins have "pleiotropic" benefits in addition to their principal action of inhibiting 2-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis? Three reports at the American Heart Association (AHA) 2008 Scientific Sessions in New Orleans, Louisiana, sought to elucidate the potential therapeutic effects mediated by these putative pleiotropic actions, addressing the questions:

  • Whether statins have potential benefits in apparently healthy people with normal or even "healthy" low-density lipoprotein cholesterol (LDL-C) levels?

  • Whether, following the disappointing results of the first 2 outcomes studies with rosuvastatin in patients with heart failure -- CORONA (COntrolled ROsuvastatin multiNAtional trial in heart failure) and GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico--Heart Failure) -- there might be a subgroup of patients with heart failure who may benefit from statin treatment?

  • Whether statins may protect against, or even induce, new-onset diabetes?


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.